Skip to content

Study · Non-randomized trial · 1978

10 results

1-deamino-8-D-arginine vasopressin in the treatment of central diabetes insipidus in childhood.

Becker DJ, Foley TP Jr

The Journal of pediatrics1 Jun 1978Cited by 29 (Europe PMC)

PMID660339 (opens in a new tab)DOI10.1016/s0022-3476(78)80389-8 (opens in a new tab)PepBankPUB-00660339
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with central diabetes insipidus, daily urine volume fell from 5.4 l untreated to 1.6 l/day with DDAVP.

    In plain wordsIn children with central diabetes insipidus, daily urine volume decreased with DDAVP compared with no therapy.

    Peptide
    Desmopressin
    Outcome
    DecreaseDaily urine volume
    Study

    n: not reported in source

    Comparator
    Without therapy
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Daily urine volume
    5.4 l
    without therapy
    Daily urine volume
    1.6 l/day
    DDAVP

    Source sentences

    Summary
    Mean daily urine volume without therapy was 5.4 l and dropped to 1.1 and 1.6 l/day while receiving pitressin and DDAVP, respectively.
    1 context sentence
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with central diabetes insipidus, DDAVP effects lasted 8 to 20 hours and varied between patients.

    In plain wordsIn children with central diabetes insipidus, DDAVP effects lasted 8 to 20 hours.

    Peptide
    Desmopressin
    Outcome
    Not applicableDuration of effect
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Effect duration
    8 to 20 hours
    DDAVP

    Source sentences

    Summary
    The duration of DDAVP effect was 8 to 20 hours, varying in individual patients.
    1 context sentence
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  3. 03HumanNon-randomized trialEfficacy outcome

    Children with partial diabetes insipidus required smaller DDAVP doses than children with complete disease.

    In plain wordsChildren with partial diabetes insipidus needed smaller DDAVP doses than children with complete disease.

    Peptide
    Desmopressin
    Outcome
    DecreaseDose requirements by disease completeness
    Study

    n: not reported in source

    Comparator
    Complete DI
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Children with partial DI required smaller doses of DDAVP and the duration of action was longer than in those with complete DI.
    1 context sentence
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  4. 04HumanNon-randomized trialEfficacy outcome

    DDAVP action lasted longer in children with partial diabetes insipidus than in children with complete disease.

    In plain wordsDDAVP effects lasted longer in children with partial diabetes insipidus than in children with complete disease.

    Peptide
    Desmopressin
    Outcome
    IncreaseDuration by disease completeness
    Study

    n: not reported in source

    Comparator
    Complete DI
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Children with partial DI required smaller doses of DDAVP and the duration of action was longer than in those with complete DI.
    1 context sentence
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with diabetes insipidus, serum electrolyte control was excellent with twice-daily DDAVP.

    In plain wordsIn children with diabetes insipidus, twice-daily DDAVP provided excellent blood electrolyte control.

    Peptide
    Desmopressin
    Outcome
    Not applicableSerum electrolyte control
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    two doses per day · intranasalAs given in this study (human).

    Source sentences

    Summary
    Control of serum electrolytes was excellent using two doses per day and nocturia was eliminated.
    2 context sentences
    Summary · context
    Children with partial DI required smaller doses of DDAVP and the duration of action was longer than in those with complete DI.
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  6. 06HumanNon-randomized trialEfficacy outcome

    In children with diabetes insipidus, twice-daily DDAVP eliminated nocturia.

    In plain wordsIn children with diabetes insipidus, twice-daily DDAVP eliminated nighttime urination.

    Peptide
    Desmopressin
    Outcome
    DecreaseNocturia
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    two doses per day · intranasalAs given in this study (human).

    Source sentences

    Summary
    Control of serum electrolytes was excellent using two doses per day and nocturia was eliminated.
    2 context sentences
    Summary · context
    Children with partial DI required smaller doses of DDAVP and the duration of action was longer than in those with complete DI.
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  7. 07HumanNon-randomized trialEfficacy outcome

    In children with diabetes insipidus, DDAVP did not alter growth hormone levels during sleep.

    In plain wordsIn children with diabetes insipidus, DDAVP did not change growth hormone levels during sleep.

    Peptide
    Desmopressin
    Outcome
    No significant changeGrowth hormone during sleep
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    DDAVP did not alter growth hormone, cortisol, or prolactin levels during sleep.
    1 context sentence
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  8. 08HumanNon-randomized trialEfficacy outcome

    In children with diabetes insipidus, DDAVP did not alter cortisol levels during sleep.

    In plain wordsIn children with diabetes insipidus, DDAVP did not change cortisol levels during sleep.

    Peptide
    Desmopressin
    Outcome
    No significant changeCortisol during sleep
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    DDAVP did not alter growth hormone, cortisol, or prolactin levels during sleep.
    1 context sentence
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  9. 09HumanNon-randomized trialEfficacy outcome

    In children with diabetes insipidus, DDAVP did not alter prolactin levels during sleep.

    In plain wordsIn children with diabetes insipidus, DDAVP did not change prolactin levels during sleep.

    Peptide
    Desmopressin
    Outcome
    No significant changeProlactin during sleep
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Endocrine and hormones
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    DDAVP did not alter growth hormone, cortisol, or prolactin levels during sleep.
    1 context sentence
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.
  10. 10HumanNon-randomized trialEfficacy outcome

    In children with central diabetes insipidus, daily urine volume was 1.6 l/day with DDAVP versus 1.1 l/day with pitressin.

    In plain wordsIn children with central diabetes insipidus, daily urine volume was higher with DDAVP than with pitressin.

    Peptide
    Desmopressin
    Outcome
    IncreaseDaily urine volume versus pitressin
    Study

    n: not reported in source

    Comparator
    Pitressin
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Daily urine volume
    1.6 l/day
    DDAVP
    Daily urine volume
    1.1 l/day
    pitressin

    Source sentences

    Summary
    Mean daily urine volume without therapy was 5.4 l and dropped to 1.1 and 1.6 l/day while receiving pitressin and DDAVP, respectively.
    1 context sentence
    Summary · context
    The effectiveness of therapy with carbamazepine and clofibrate (oral therapy), intramuscular pitressin-in-oil, and intranasal 1-deamino-8-D-arginine vasopressin has been compared in 15 children with partial or complete central diabetes insipidus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.